

Thailand Morning Cuppa

Top Story

Minor International (MINT TB, BUY, TP: THB40.50)

3Q22 Results Beat Pre-Pandemic Levels; Still BUY

Results Review

Keep BUY, new THB40.50TP (DCF) from THB42.50, 36% upside. Minor International's robust 3Q22 results were above pre-pandemic levels, and earnings may strongly expand over 4Q22-2023. Its share price lags local peers on market concerns – leading to an attractive FY23F valuation.

Analyst: Vatcharut Vacharawongsith +66 2088 9736

Today's Report: <u>Minor International : 3Q22 Results Beat Pre-Pandemic Levels; Still BUY</u> (11 Nov 2022) Previous Report: <u>Minor International : Strong European Hotels Still Driving Profits; BUY</u> (19 Aug 2022)

Other Story

PTT (PTT TB, BUY, TP: THB51)

Long-Term Potential Still Intact; Maintain BUY Results Review

Keep BUY and THB51 TP, 49% upside and c.5% yield. PTT posted an expected decline in its 3Q22 performance, mainly impacted by weakness in its petrochemical and refinery business, on the back of lower demand and high production costs. However, PTT is working to capitalise on future business trends, such as in the EV-related space and innovations in health and environmental products, which have strong long-term potential.

Analyst: Athipu Visavaveja +66 2088 9627

Today's Report: <u>PTT : Long-Term Potential Still Intact; Maintain BUY</u> (11 Nov 2022)

Previous Report: PTT : Site Visit: Positive On Long-Term Potential; BUY (3 Oct 2022)






Thailand Daily 11 November 2022

1,626.0							Index	Chg	Chg (%)	YTD (
1.624.0						Thailand (SET)	1619.23	-3.22	-0.20%	-2.3
622.0 -	~~	~~				Thailand (SET50)	987.63	-1.76	-0.18%	-0.3
520.0 -				\sim		Thailand (SET100)	2217.58	-1.79	-0.08%	-2.1
618.0 -	N		•	•	_	USA (Dow Jones)	33715.37	1201.43	3.70%	-7.2
16.0 -						USA (S&P500)	3956.37	207.80	5.54%	-17.0
14.0 12.0						USA (Nasdaq)	11114.15	760.98	7.35%	-29.0
12.0						UK (FTSE)	7375.34	79.09	1.08%	-0.
08.0						Singapore (FSSTI)	3173.18	7.68	0.24%	1.
06.0	.20 44.05 44.44	0 4 0 4 5 4	4.45.44.50	45:05 40:0		Hong Kong (Hang Seng)	16081.04	-277.48	-1.70%	-31.
9.00 10	:30 11:05 11:40	J 12.15 1	4.15 14:50	10.20 10.0	0.35	Japan (Nikkei)	27446.10	-6.23	-0.02%	-4.
		2020	2021	2022F	2023F	Malaysia (KLCI)	1449.74	3.55	0.25%	-7.
)		37.27	15.12	15.48	14.70	China (SHANGHAI SE)	3036.13	-12.03	-0.39%	-16.
x) %)		1.56 2.75	1.77 2.65	1.63 2.82	1.54 3.02	Indonesia (JCI)	6966.84	-103.25	-1.46%	5.
ue by inves	tor Type: Daily		Buy (THBm)	Sell (THBm)	Net (THBm)					
1			4,989.53	4,443.94	545.59	Foreign Exchange Rates	/ Oil Marke	t Closed	Chq	Chq
У			4,606.20 30,833.97	4,588.82 29,812.87	17.38 1,021.10	Baht (Onshore)		36.16	-0.03	Ong 0
			19,371.93	20,955.99	-1,584.07	Yen		141.61	0.63	-0
lue by inves	tor Type			MTD (THBm)	YTD (THBm)	Euro		1.02	0.00	-0
				-10,739.56	-150,891.83	Oil Price (USD/barrel)				
ry				-4,952.01 18 779 43	-4,818.92 177,664.12	Brent		93.49	0.77	0
					-21,953.36	Nymex-Crude Light		86.43	-0.04	-0
ndex Future		Short	Net	MTD	YTD					
n	40,765 88,051	42,949 78,141	-2,184 9,910	-5,732 64,742	-1,999 133,855					
1	121,344	129,070	-7,726	-59,010	-131,856					
Fund Flows		226.9	MTD	YTD	YoY					
nailand	28.1	236.8	502.1	5246.2	7172.9					





Top BUYs			
	TP (THB)	Upside (%)	Catalysts
Airports of Thailand (AOT TB)	82	9.70	 Expect smaller negative earnings YoY and QoQ in 4QFY22. Improving flight and passenger numbers should strongly support earnings – mainly via passenger service charges and concessions revenues. Expect FY22F core loss of THB9.4bn, which will turn to a core profit of THB11.31bn in FY23. Possible easing of COVID-19 restrictions globally may trigger more foreign arrivals and Thai departures in the near term, ie from 1HFY23 onwards. AOT's Bangkok Suvarnabhumi Airport (BKK) has room to double capacity in six years. The new Satellite Terminal (SAT-1) is scheduled to open in 4QFY23 (Sep) and may help drive an earnings jump in FY24.
Bangkok Dusit Medical Services (BDMS TB)	35	12.00	 Expect 3Q22's THB2.77bn core profit (+10% YoY, +4% QoQ). Hospital occupancy rates rise to 75% (3Q21: 71%, 2Q22: 69%). Foreign patient revenue may ramp up to 95% of pre-pandemic levels (2Q22: 91%, FY21: 55%) and it may return to normal in 4Q22. 4Q22F earnings may grow moderately YoY and slightly QoQ. Rising general treatments from local and foreign patients and the uptrend in profit margins may limit impact of a gradual decline in pandemic-related income. Expect strong 47% net profit growth in 2022, with resilient 10% growth in 2023. 2022 bottomline and profit margins should exceed 2019 levels. BDMS remains our Thai healthcare Top Pick.
Central Pattana (CPN TB)	76.75	9.64	 Expect 3Q22 earnings to jump YoY and gradually increase QoQ. Operational momentum for all its businesses for July-August may be stronger than in 2Q22. Customer traffic to CPN malls will ramp up throughout 2H22 (2Q22: 85% of 2019 levels), benefitting from a recovery in out-of-home activities and Thailand's full re-opening to international tourists. CPN's rental rate discount is quite stable (15% on average) as tenants have recovered after COVID-19, and It will attain a stronger rental income from tenants with revenue-sharing contract
Central Retail Corporation (CRC TB)	48	18.52	 Normalising store operations may keep the earnings turnaround ticking on in 3Q22 vs the lockdowns that led to the temporary shuttering of CRC's Thailand and Vietnam stores – this, in turn, resulted in a steep THB2.24bn core loss in 3Q21. Its 3Q22F SSSG may be close to +50% YoY. Rising post-pandemic demand and a rebound in tourism may drive sales growth for the company's fashion and food wings throughout 3Q-4Q while the planned opening of more new stores in 2H22 could support the hardline segment's turnover. Expect a core profit of THB5.61bn for 2022, jumping from an extremely low base of THB189m in 2021, and it will expand 45% to pre-pandemic levels in 2023.
Home Product Center (HMPRO TB)	18.70	28.97	 Expect 3Q22's THB1.50bn net profit (+72% YoY, -1% QoQ). Assume +15% YoY SSSG for HomePro Thailand (3Q21: -17.0%, 2Q22: -1.1%), net rental and other incomes growth of 80% YoY and 2% QoQ. GPM should rise YoY and QoQ on a higher sales mix of private label products to 20.5% (9M21: 19.5%). 4Q22F earnings may grow YoY and QoQ, to be the strongest quarter. Support factors: a high season for retail, home improvement demand post flooding, the opening of one new HomePro and a total three new Mega Home stores, and stronger recurring income. Expect a strong 17% earnings growth in 2022 and a resilient 9% growth in 2023.
Kasikornbank (KBANK TB)	175	18.24	 KBANK is ready for the new digital era, as it has business units that are fully equipped with new tech. This will be hidden value waiting to be unlocked in future. Historical price trends suggest its share price should outperform peers when the economy is on a recovery path. KBANK offers lowest CIR in the banking industry, while its asset quality remains manageable.
Land and Houses (LH TB)	9.45	N/A	 Land and Houses will focus on: i) Conservative increases in targets for project sales revenue and presales and ii) a major focus on boosting new project launches that may include new condominiums. This key developer's plan may highlight industry trends for 2022, and its competitors may follow suit by ramping up project launches more aggressively. 1H22 overall presale was in line with FY22 business target at 50% of full-year target. Low-rise project presale in 2Q22 slightly declined 2%YoY while condominium presale jumped strongly 50%YoY from the low-base level. Its presales progress was in line with other leading developers. The country's re-opening will also bode well for the company's recurring income assets including hotel and shopping mall that can start to generate revenue growth from FY23 onwards.







Top BUYs

	TP (THB)	Upside (%)	Catalysts
РТТ (РТТ ТВ)	51	48.91	 In early October, OPEC+ decided to decrease overall production by 2mbpd from the August levels, starting November, which is beyond estimation. This event leads to supply tight and make oil prices to stay at high level. PTT is entering high season in 4Q22 in accordance with high demand of heating energy for cold weather as well as higher production from gas business. PTT is able to pay an attractive dividend of 5%. In addition, PTT is still working to capitalise on future business trends, such as in the EV-related space, and innovations in health and environmental products.
Thai Union Group (TU TB)	24	38.73	 TU is progressing further in terms of debuting its pet food business on the stock market after it began the filing process with the SEC. The pet food business provides higher margins of c.23-27% vs normal TU's margin c.17-18%. Hence, the newly listed entity can potentially trade at high valuations and add value to TU. 4Q22 earnings are also expected to recover from better economic reopening after the pandemic and the rise in consumption spending. Tuna costs remain under manageable levels and should be under less pressure after the passing of the fish aggregating devices banning period.
TISCO Financial (TISCO TB)	114	17.22	• Due to its solid asset quality and healthy capital position, as well as its above-average dividend yields of 7%.





Recent Stories

To access the following reports, please click on the link: RHB | Thailand Morning Cuppa : 10 November 2022 Berli Jucker : Robust YoY Growth In 3Q22; Keep BUY Osotspa : Weaker-Than-Expected 3Q22 Numbers; Still BUY

RHB | Thailand Morning Cuppa : 9 November 2022 PTT Oil and Retail Business : On Recovery Road Post The Low Season; BUY

RHB | Thailand Morning Cuppa : 8 November 2022 Real Estate : Hoping For New Catalysts

<u>RHB | Thailand Morning Cuppa : 7 November 2022</u> Central Retail Corporation : Another Earnings Turnaround In 3Q22; Still BUY

 RHB | Thailand Morning Cuppa : 4 November 2022

 Thai Union Group : High-Value Products Aim Post Strong 3Q22; BUY

 LPN Development : Surprised By 3Q22 Asset Sale; Still SELL

 Advanced Info Service : A Slow Advance

<u>Thailand Morning Cuppa : 3 November 2022</u> Home Product Center : Resilient 4Q As Usual; Keep BUY

RHB | Thailand Morning Cuppa : 2 November 2022 AP (Thailand) : Another Likely New High In FY22; Stay BUY

 RHB | Thailand Morning Cuppa : 1 November 2022

 Charoen Pokphand Foods : Strong 2H22, Some Raw Material Concerns; BUY

 ESG Thematic Conference : Takeaways From RHB ESG Thematic Conference

RHB | Thailand Morning Cuppa : 31 October 2022 Amata Corp : Latecomer To The Party; Keep SELL

RHB | Thailand Morning Cuppa : 28 October 2022 Central Pattana : Seeks Healthy 3Q22 Performance; Keep BUY

<u>RHB | Thailand Morning Cuppa : 27 October 2022</u> <u>Siam Cement : Deep Down Low; Maintain BUY</u> <u>PTT Exploration & Production : Strong 3Q22, Enters Winter On High Volume; BUY</u> <u>Market Strategy : Macroeconomic Risks Still a Drag...</u>

RHB | Thailand Morning Cuppa : 26 October 2022 Home Product Center : Favourable 3Q22 Results In Line; Keep BUY

RHB | Thailand Morning Cuppa : 25 October 2022 Supalai : Ground Checks Of Supalai's SDH, Condos; BUY

<u>RHB | Thailand Morning Cuppa : 21 October 2022</u> <u>Thai Union Group : Solid 3Q22 Expected, Petcare Spin-Off Nears; BUY</u>

RHB | Thailand Morning Cuppa : 20 October 2022 LPN Development : Slow Performance As Ever; Maintain SELL

<u>RHB | Thailand Morning Cuppa : 19 October 2022</u> Market Strategy : In 4Q22, Accumulate The Big-Cap Stocks

<u>RHB | Thailand Morning Cuppa : 18 October 2022</u> Osotspa : 3Q22 Earnings Likely To Bottom Out; Still BUY

RHB | Thailand Morning Cuppa : 17 October 2022 PTT Oil and Retail Business : Positive Post Ayutthaya Site Visit; Keep BUY

<u>RHB | Thailand Morning Cuppa : 12 October 2022</u> Berli Jucker : Rental Income To Still Drive Earnings; Keep BUY

RHB | Thailand Morning Cuppa : 11 October 2022 Real Estate : Presales Mixed Bag In 3Q22





RHB Guide to Investment Ratings

 Buy:
 Share price may exceed 10% over the next 12 months

 Trading Buy:
 Share price may exceed 15% over the next 3 months, however longer-term outlook remains uncertain

 Neutral:
 Share price may fall within the range of +/- 10% over the next 12 months

 Take Profit:
 Target price has been attained. Look to accumulate at lower levels

 Sell:
 Share price may fall by more than 10% over the next 12 months

 Not Rated:
 Stock is not within regular research coverage

Investment Research Disclaimers

RHB has issued this report for information purposes only. This report is intended for circulation amongst RHB and its affiliates' clients generally or such persons as may be deemed eligible by RHB to receive this report and does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report. This report is not intended, and should not under any circumstances be construed as, an offer or a solicitation of an offer to buy or sell the securities referred to herein or any related financial instruments.

This report may further consist of, whether in whole or in part, summaries, research, compilations, extracts or analysis that has been prepared by RHB's strategic, joint venture and/or business partners. No representation or warranty (express or implied) is given as to the accuracy or completeness of such information and accordingly investors should make their own informed decisions before relying on the same.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to the applicable laws or regulations. By accepting this report, the recipient hereof (i) represents and warrants that it is lawfully able to receive this document under the laws and regulations of the jurisdiction in which it is located or other applicable laws and (ii) acknowledges and agrees to be bound by the limitations contained herein. Any failure to comply with these limitations may constitute a violation of applicable laws.

All the information contained herein is based upon publicly available information and has been obtained from sources that RHB believes to be reliable and correct at the time of issue of this report. However, such sources have not been independently verified by RHB and/or its affiliates and this report does not purport to contain all information that a prospective investor may require. The opinions expressed herein are RHB's present opinions only and are subject to change without prior notice. RHB is not under any obligation to update or keep current the information and opinions expressed herein or to provide the recipient with access to any additional information. Consequently, RHB does not guarantee, represent or warrant, expressly or impliedly, as to the adequacy, accuracy, reliability, fairness or completeness of the information and opinion contained in this report. Neither RHB (including its officers, directors, associates, connected parties, and/or employees) nor does any of its agents accept any liability for any direct, indirect or consequential losses, loss of profits and/or damages that may arise from the use or reliance of this research report and/or further communications given in relation to this report. Any such responsibility or liability is hereby expressly disclaimed.

Whilst every effort is made to ensure that statement of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable and must not be construed as a representation that the matters referred to therein will occur. Different assumptions by RHB or any other source may yield substantially different results and recommendations contained on one type of research product may differ from recommendations contained in other types of research. The performance of currencies may affect the value of, or income from, the securities or any other financial instruments referenced in this report. Holders of depositary receipts backed by the securities discussed in this report assume currency risk. Past performance is not a guide to future performance. Income from investments may fluctuate. The price or value of the investments to which this report relates, either directly or indirectly, may fall or rise against the interest of investors.

This report may contain comments, estimates, projections, forecasts and expressions of opinion relating to macroeconomic research published by RHB economists of which should not be considered as investment ratings/advice and/or a recommendation by such economists on any securities discussed in this report.

This report does not purport to be comprehensive or to contain all the information that a prospective investor may need in order to make an investment decision. The recipient of this report is making its own independent assessment and decisions regarding any securities or financial instruments referenced herein. Any investment discussed or recommended in this report may be unsuitable for an investor depending on the investor's specific investment objectives and financial position. The material in this report is general information intended for recipients who understand the risks of investing in financial instruments. This report does not take into account whether an investment or course of action and any associated risks are suitable for the recipient. Any recommendations contained in this report must therefore not be relied upon as investment advice based on the recipient's personal circumstances. Investors should make their own independent evaluation of the information contained herein, consider their own investment objective, financial situation and particular needs and seek their own financial, business, legal, tax and other advice regarding the appropriateness of investing in any securities or the investment strategies discussed or recommended in this report.

This report may contain forward-looking statements which are often but not always identified by the use of words such as "believe", "estimate", "intend" and "expect" and statements that an event or result "may", "will" or "might" occur or be achieved and other similar expressions. Such forward-looking statements are based on assumptions made and information currently available to RHB and are subject to known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievement to be materially different from any future results, performance or achievement, expressed





or implied by such forward-looking statements. Caution should be taken with respect to such statements and recipients of this report should not place undue reliance on any such forward-looking statements. RHB expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or circumstances after the date of this publication or to reflect the occurrence of unanticipated event The use of any website to access this report electronically is done at the recipient's own risk, and it is the recipient's sole responsibility to take precautions to ensure that it is free from viruses or other items of a destructive nature. This report may also provide the addresses of, or contain hyperlinks to, websites. RHB takes no responsibility for the content contained therein. Such addresses or hyperlinks (including addresses or hyperlinks to RHB own website material) are provided solely for the recipient's convenience. The information and the content of the linked site do not in any way form part of this report. Accessing such website or following such link through the report or RHB website shall be at the recipient's own risk.

This report may contain information obtained from third parties. Third party content providers do not guarantee the accuracy, completeness, timeliness or availability of any information and are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Third party content providers give no express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Third party content providers shall not be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content.

The research analysts responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously. The research analysts that authored this report are precluded by RHB in all circumstances from trading in the securities or other financial instruments referenced in the report, or from having an interest in the company(ies) that they cover.

The contents of this report is strictly confidential and may not be copied, reproduced, published, distributed, transmitted or passed, in whole or in part, to any other person without the prior express written consent of RHB and/or its affiliates. This report has been delivered to RHB and its affiliates' clients for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above. By electing to view or accepting a copy of this report, the recipients have agreed that they will not print, copy, videotape, record, hyperlink, download, or otherwise attempt to reproduce or re-transmit (in any form including hard copy or electronic distribution format) the contents of this report. RHB and/or its affiliates accepts no liability whatsoever for the actions of third parties in this respect.

The contents of this report are subject to copyright. Please refer to Restrictions on Distribution below for information regarding the distributors of this report. Recipients must not reproduce or disseminate any content or findings of this report without the express permission of RHB and the distributors.

The securities mentioned in this publication may not be eligible for sale in some states or countries or certain categories of investors. The recipient of this report should have regard to the laws of the recipient's place of domicile when contemplating transactions in the securities or other financial instruments referred to herein. The securities discussed in this report may not have been registered in such jurisdiction. Without prejudice to the foregoing, the recipient is to note that additional disclaimers, warnings or qualifications may apply based on geographical location of the person or entity receiving this report.

The term "RHB" shall denote, where appropriate, the relevant entity distributing or disseminating the report in the particular jurisdiction referenced below, or, in every other case, RHB Investment Bank Berhad and its affiliates, subsidiaries and related companies.

RESTRICTIONS ON DISTRIBUTION

Malaysia

This report is issued and distributed in Malaysia by RHB Investment Bank Bhd. The views and opinions in this report are our own as of the date hereof and is subject to change. If the Financial Services and Markets Act of the United Kingdom or the rules of the Financial Conduct Authority apply to a recipient, our obligations owed to such recipient therein are unaffected. RHB Investment Bank Bhd has no obligation to update its opinion or the information in this report.

Thailand

This report is issued and distributed in the Kingdom of Thailand by RHB Securities (Thailand) PCL, a licensed securities company that is authorised by the Ministry of Finance, regulated by the Securities and Exchange Commission of Thailand and is a member of the Stock Exchange of Thailand. The Thai Institute of Directors Association has disclosed the Corporate Governance Report of Thai Listed Companies made pursuant to the policy of the Securities and Exchange Commission of Thailand) PCL does not endorse, confirm nor certify the result of the Corporate Governance Report of Thai Listed Companies.

Indonesia

This report is issued and distributed in Indonesia by PT RHB Sekuritas Indonesia. This research does not constitute an offering document and it should not be construed as an offer of securities in Indonesia. Any securities offered or sold, directly or indirectly, in Indonesia or to any Indonesian citizen or corporation (wherever located) or to any Indonesian resident in a manner which constitutes a public offering under Indonesian laws and regulations must comply with the prevailing Indonesian laws and regulations.





Singapore

This report is issued and distributed in Singapore by RHB Bank Berhad (through its Singapore branch) which is an exempt capital markets services entity and an exempt financial adviser regulated by the Monetary Authority of Singapore. RHB Bank Berhad (through its Singapore branch) may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, RHB Bank Berhad (through its Singapore branch) accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact RHB Bank Berhad (through its Singapore branch) in respect of any matter arising from or in connection with the report.

United States

This report was prepared by RHB is meant for distribution solely and directly to "major" U.S. institutional investors as defined under, and pursuant to, the requirements of Rule 15a-6 under the U.S. Securities and Exchange Act of 1934, as amended (the "Exchange Act") via a registered U.S. broker-dealer as appointed by RHB from time to time. Accordingly, any access to this report via Bursa Marketplace or any other Electronic Services Provider is not intended for any party other than "major" US institutional investors (via a registered U.S broker-dealer), nor shall be deemed as solicitation by RHB in any manner. RHB is not registered as a broker-dealer in the United States and currently has not appointed a U.S. broker-dealer. Additionally, RHB does not offer brokerage services to U.S. persons. Any order for the purchase or sale of all securities discussed herein must be placed with and through a registered U.S. broker-dealer as appointed by RHB from time to time as required by the Exchange Act Rule 15a-6. For avoidance of doubt, RHB reiterates that it has not appointed any U.S. broker-dealer during the issuance of this report. This report is confidential and not intended for distribution to, or use by, persons other than the recipient and its employees, agents and advisors, as applicable. Additionally, where research is distributed via Electronic Service Provider, the analysts whose names appear in this report are not registered or gualified as research analysts in the United States and are not associated persons of any registered U.S. broker-dealer as appointed by RHB from time to time and therefore may not be subject to any applicable restrictions under Financial Industry Regulatory Authority ("FINRA") rules on communications with a subject company, public appearances and personal trading. Investing in any non-U.S. securities or related financial instruments discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in the United States. The financial instruments discussed in this report may not be suitable for all investors. Transactions in foreign markets may be subject to regulations that differ from or offer less protection than those in the United States.

Please refer to the following link (<u>RHB Research conflict disclosures – Nov 2022</u>) and the Disclosure of Conflict of Interest in each of the research reports provided in this email for more details.

Kuala Lumpur	Singapore
RHB Investment Bank Bhd Level 3A, Tower One, RHB Centre Jalan Tun Razak Kuala Lumpur Malaysia Tel : +(60) 3 9280 8888 Fax : +(60) 3 9200 2216	RHB Bank Berhad (Singapore branch) 90 Cecil Street #04-00 RHB Bank Building Singapore 069531 Fax : +65 6509 0470
Jakarta	Bangkok

